Narrative review highlights interleukin-39’s role in diagnosing type 2 diabetes, suggesting its potential as a biomarker.
It is a worldwide complicated metabolic disorder linked to impaired insulin action, chronic low-grade inflammation, and dysfunctional β-cells. Interleukin-39 (IL-39) has been identified as a new cytokine associated with immune modulation and metabolic dysfunction recently. Recent research has highlighted IL-39 as a biomarker in and an interventional target for T2DM. That review provides a brief of the present evidence on IL‑39 biology and its relevance to T2DM pathophysiology.
No takes yet. Share an insight, caveat, or question.
Hamood et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: